SCHEMBL90476

SCHEMBL90476

CC1(C)OB(c2ccccc2)OC1(C)C

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 14/20 0.76
LPL P06858 13/20 0.76
P4HB P07237 1/20 0.51
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
CA12 O43570 1/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47
F11 P03951 2/20 0.46
F2 P00734 1/20 0.42
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42
PRSS3 P35030 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19046610 1.00 LIPG (0.76) LIPGLPLP4HBCA1CA2
Ammonia Solution, Strong SCHEMBL4385797 0.98 LIPG (0.73) LIPGLPLP4HBCA1CA2
SCHEMBL17783266 0.91 LIPG (0.66) LIPGLPLP4HBCA1CA2
SCHEMBL15743263 0.88 LIPG (0.61) LIPGLPLP4HBCA1CA2
SCHEMBL228212 0.87 LPL (0.71) LIPGLPLP4HBCA1CA2
SCHEMBL10021061 0.87 LIPG (1.00) LIPGLPLP4HBCA1CA2
SCHEMBL18270366 0.87 LIPG (1.00) LIPGLPLP4HBCA1CA2
SCHEMBL18134357 0.87 LIPG (1.00) LIPGLPLP4HBCA1CA2
SCHEMBL476870 0.87 LIPG (1.00) LIPGLPLP4HBCA1CA2
SCHEMBL22383015 0.86 LIPG (0.65) LIPGLPLP4HBCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1827 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2026-05-19 US claimed
US-20220263102-A1 ELIMINATING VOLTAGE DELAY AND STABILIZING IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2022-08-18 US claimed
CN-113136020-B Water-based polyurethane polymer and preparation method thereof, single-component water-based polyurethane waterproof coating and preparation method and application thereof 万华化学集团股份有限公司 2022-08-05 CN claimed
CN-114605602-A Hierarchical pore covalent organic framework compound and preparation method and application thereof 浙江工业大学 2022-06-10 CN claimed
EP-3997748-A1 ELIMINATION OF VOLTAGE DELAY AND STABILIZATION OF IMPEDANCE BY ELECTROLYTE ADDITIVES IN ALKALI METAL ELECTROCHEMICAL CELLS LITRONIK Batterietechnologie GmbH (DE) 2022-05-18 EP claimed
CN-114342141-A Elimination of voltage delay and stabilization of impedance by electrolyte additives in alkali metal electrochemical cells 利特罗尼克电池技术有限公司 2022-04-12 CN claimed
US-10698121-B2 10B enriched plastic scintillators for application in thermal neutron detection, methods of making and using the same SELLINGER ALAN (US) 2020-06-30 US claimed
US-20190041533-A1 10B ENRICHED PLASTIC SCINTILLATORS FOR APPLICATION IN THERMAL NEUTRON DETECTION, METHODS OF MAKING AND USING THE SAME SELLINGER ALAN (US) 2019-02-07 US claimed
EP-2714660-B1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2018-09-26 EP claimed
CN-107074825-A Benzyl substituted indazoles as BUB1 kinase inhibitors 拜耳制药股份公司 2017-08-18 CN claimed
EP-3194381-A1 BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2017-07-26 EP claimed
EP-3194380-A1 BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2017-07-26 EP claimed
WO-2016042081-A1 BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-03-24 WO claimed
WO-2016042080-A1 BENZYL SUBSTITUTED INDAZOLES AS BUB1 KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-03-24 WO claimed
US-20120309724-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-12-06 US claimed
WO-2012166390-A1 NEPRILYSIN INHIBITORS THERAVANCE, INC. (US) 2012-12-06 WO claimed
WO-2026104431-A1 ORGANIC LIGHT-EMITTING DEVICE MERCK PATENT GMBH (DE) 2026-05-21 WO disclosed
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells LITRONIK BATTERIETECHNOLOGIE GMBH (DE) 2026-05-19 US disclosed
EP-1127060-A1 HYDROBORONATION PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2001-08-29 EP disclosed
WO-2000027853-A1 HYDROBORONATION PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309724-A1 NEPRILYSIN INHIBITORS MME, REN, ACE LIPG 1062/4885LPL 1277/4885P4HB 4167/4885
US-12633548-B2 Eliminating voltage delay and stabilizing impedance by electrolyte additives in alkali metal electrochemical cells KCNN1, HCN4, KCNN2 LIPG 4122/4885LPL 4624/4885P4HB 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.